NCT02780154 is a Phase 1 clinical trial of PfSPZ (7G8) Challenge in Plasmodium Falciparum Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Who is sponsoring NCT02780154?

NCT02780154 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What drugs are being tested in NCT02780154?

Interventions in NCT02780154: PfSPZ (7G8) Challenge, PfSPZ (NF54) Challenge.

What condition does NCT02780154 study?

NCT02780154 studies Plasmodium Falciparum Infection.

Is NCT02780154 still recruiting?

NCT02780154 is currently completed. Last updated 28 January 2019.

Last reviewed 2019-01-28 · How we verify

NCT02780154

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PfSPZ Challenge in Non-immune Adults in Baltimore, USA

Completed Phase 1 Last updated 28 January 2019

What this trial tests

Phase 1 trial testing PfSPZ (7G8) Challenge in Plasmodium Falciparum Infection in 30 participants. Completed in 15 December 2016.

Timeline

25 August 2016

Primary endpoint
15 December 2016

15 December 2016

Quick facts

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	30
Start date	25 August 2016
Primary completion	15 December 2016
Estimated completion	15 December 2016
Sites	1 location across United States

Drugs / interventions tested

PfSPZ (7G8) Challenge — full drug profile →
PfSPZ (NF54) Challenge — full drug profile →

Conditions studied

Plasmodium Falciparum Infection — all drugs for Plasmodium Falciparum Infection →

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Who can join

Adults 18 to 45, any sex, with Plasmodium Falciparum Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center, randomized and controlled human study to optimize controlled human malaria infection (CHMI) administered by direct venous inoculation (DVI). 36 healthy adults aged between 18 and 45 years, will be randomized to one of five groups and will be inoculated with PfSPZ Challenge DVI. Participation duration is estimated to be 2 months, while the study duration is planned to be 4 months. The primary objective of this study is to assess the safety and reactogenicity of PfSPZ Challenge administered by DVI using 7G8 and NF54 P. falciparum strains.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Dose-Dependent Infectivity of Aseptic, Purified, Cryopreserved Plasmodium falciparum 7G8 Sporozoites in Malaria-Naive Adults.
Laurens MB, Berry AA, Travassos MA, Strauss K, et al · · 2019 · cited 26× · PMID 31419294 · DOI 10.1093/infdis/jiz410
The Controlled Human Malaria Infection Experience at the University of Maryland.
Friedman-Klabanoff DJ, Laurens MB, Berry AA, Travassos MA, et al · · 2019 · cited 18× · PMID 30675854 · DOI 10.4269/ajtmh.18-0476
Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome.
Berry AA, Obiero JM, Travassos MA, Ouattara A, et al · · 2021 · cited 6× · PMID 34518543 · DOI 10.1038/s41541-021-00363-y
Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to Plasmodium falciparum peptides.
Friedman-Klabanoff DJ, Jensen TL, Lyke KE, Laurens MB, et al · · 2025 · PMID 41030440 · DOI 10.3389/fimmu.2025.1641280

Verify or expand the search:

Other trials of PfSPZ (7G8) Challenge

Trials testing the same drug.

NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI · Phase 1 · active not recruiting

Other National Institute of Allergy and Infectious Diseases (NIAID) trials

Trials by the same sponsor.

NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · not yet recruiting
NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT06987318 — A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) · Phase 1 · not yet recruiting
NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of · Phase 1, PHASE2 · not yet recruiting
NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02780154 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID)
Last refreshed: 28 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02780154.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing